SQ-LIP-000005 · v1.3 (archived) · View current version →
Does lipedema increase the prevalence of joint hypermobility?
Based on currently indexed evidence, lipedema appears to be associated with an elevated prevalence of joint hypermobility, though the evidence is observational and uncontrolled. A cross-sectional cohort (n=670) reported hypermobility in approximately 44% of adult lipedema patients (60% in childhood; moderate quality), and multiple reviews and a consensus standard-of-care guideline converge on a roughly 50% prevalence, with hypermobility sometimes characterized as consistent with hypermobile Ehlers-Danlos syndrome (hEDS) and flagged as a comorbidity contributing to joint disease and joint loading. However, these are largely crude, unadjusted prevalence figures: most supporting sources are narrative reviews or consensus guidelines (low quality) lacking non-lipedema comparison groups, and one cohort examining hEDS and lipedema together does not establish a direct causal link. No randomized or longitudinal evidence demonstrates that lipedema increases hypermobility, and the consistency of the ~44-50% estimates rests substantially on overlapping or cited prior data rather than independent controlled studies.
Knowledge freshness = share of the 6 indexed evidence sources from the last 5 years (newest 2026, oldest 2018) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
supporting contradicting refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline. The hollow ring marks the first time this topic appears in the literature.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
What changed in this version
This update added two low-quality supporting sources (a narrative review citing a 160-patient study and an American consensus standard-of-care guideline) reporting ~50% hypermobility prevalence consistent with hEDS, reinforcing the prior ~44% estimate without adding controlled or longitudinal evidence.
Supporting claims
- SCR-LIP-000017 supporting
Joint hypermobility (Hypermobility Spectrum Disorder) is a frequent comorbidity of lipedema, present in approximately 44% of adult patients in a cross-sectional cohort.
Lipedema and Hypermobility Spectrum Disorders Sharing Pathophysiology: A Cross-Sectional Observational Study — Fiengo & Sbarbati (2025) - SCR-LIP-000055 supporting
The article reports that patients with lipedema frequently exhibit connective tissue laxity and hypermobility, suggesting a potential association between lipedema and increased prevalence of joint hypermobility.
Comorbidities in lipedema: toward a systemic perspective – a narrative review — Fiengo & Sbarbati (2026) - SCR-LIP-000056 supporting
The article discusses the high prevalence of generalized joint hypermobility in women with lipedema, suggesting a link that may increase joint loading and contribute to knee pain.
Chondromalacia in Lipedema: The Sarcopenic–Valgus Cascade That Keeps Getting Missed — Amato (2025) - SCR-LIP-000145 supporting
In a review citing a prior study of 160 lipedema patients, joint hypermobility was reported in over 50% of patients, and hypermobility associated with lipedema was noted as a risk factor for joint disease and aortic stiffness.
Lipedema: friend and foe — Torre et al. (2018) - SCR-LIP-000146 supporting
An American consensus standard-of-care guideline reports that joint hypermobility occurs in approximately 50% of women with lipedema, consistent with hypermobile Ehlers-Danlos syndrome (hEDS), listed as a comorbidity (GRADE 1.9 [A]).
Standard of care for lipedema in the United States — Herbst et al. (2021)
Contradictory claims
- None indexed yet.
Refining / context
- SCR-LIP-000057 context
The article investigates the relationship between joint hypermobility and adipose disorders, including lipedema, but does not provide direct evidence on whether lipedema increases the prevalence of joint hypermobility.
Intersection between hypermobile Ehlers-Danlos syndrome and adipose disorders: investigating fascial remodeling with ultrasound imaging — Wang et al. (2025)
Major uncertainty
No controlled (lipedema vs. non-lipedema) or longitudinal data establish whether lipedema truly increases hypermobility prevalence above background rates or whether the association is causal; diagnostic criteria for both conditions are heterogeneous, and the convergent ~50% estimates derive largely from low-quality reviews and consensus documents citing overlapping prior data.
Version history
- SQ-LIP-000005 · v1.3 — 2026-05-31 — This update added two low-quality supporting sources (a narrative review citing a 160-patient study and an American consensus standard-of-care guideline) reporting ~50% hypermobility prevalence consistent with hEDS, reinforcing the prior ~44% estimate without adding controlled or longitudinal evidence. · view this version
- SQ-LIP-000005 · v1.2 — 2026-05-30 — This update added that while the relationship between joint hypermobility and adipose disorders, including lipedema, is investigated, there is no direct evidence on whether lipedema increases the prevalence of joint hypermobility. Answer reviewed and tightened by curator for rigor. · view this version
- SQ-LIP-000005 · v1.1 — 2026-05-30 — This update added claims that further support the association between lipedema and joint hypermobility, highlighting connective tissue laxity and its potential impact on joint loading and knee pain. · view this version
- SQ-LIP-000005 · v1.0 — 2026-05-30 — founding index (6 claims) · view this version
Key references
DOI:10.3390/jcm14207195 · DOI:10.1007/s10238-026-02157-9 · DOI:10.7759/cureus.95299 · DOI:10.1007/s44162-025-00113-x · DOI:10.1515/hmbci-2017-0076 · DOI:10.1177/02683555211015887